Open Access. Powered by Scholars. Published by Universities.®
Biomedical Engineering and Bioengineering Commons™
Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Biomedical Engineering and Bioengineering
Influence Of Host Cell Defence During Influenza Vaccine Production In Mdck Cells, Timo Frensing, Claudius Seitz, Bjoern Heynischotto-Von-Guericke, Udo Reichl
Influence Of Host Cell Defence During Influenza Vaccine Production In Mdck Cells, Timo Frensing, Claudius Seitz, Bjoern Heynischotto-Von-Guericke, Udo Reichl
Vaccine Technology III
For cell culture-based influenza vaccine production virus yield optimisation is of crucial importance. In particular, with the recent threat of the new H1N1 pandemic, not only seasonal vaccines but also pre-/pandemic vaccines have to be supplied in large quantities. In vivo influenza replication is limited by the immune system, but for production cell lines the impact of cellular defence mechanisms on virus yield is unknown. In influenza-infected adherent Madin-Darby canine kidney (MDCK) cells the interferon (IFN) response and subsequent induction of the antiviral state was monitored. Virus yield and host cell signalling intensity were strain-dependent. By over-expression of viral antagonists …
Clinical Development Of Formulated Therapeutic And Prophylactic Dna-Based Vaccines, Alain Rolland
Clinical Development Of Formulated Therapeutic And Prophylactic Dna-Based Vaccines, Alain Rolland
Vaccine Technology III
Over the recent years, plasmid DNA vaccines have reached licensure against infectious hematopoietic necrosis virus in farmed salmon (Canada), West Nile virus in horses and metastatic melanoma in dogs (United States). A number of approaches are currently evaluated in clinical trials to enhance the potency of DNA vaccines in humans, including formulation of DNA with delivery systems and adjuvants as well as administration of DNA with devices. This presentation will report on the development of TransVaxTM, a poloxamer-formulated therapeutic DNA vaccine against human cytomegalovirus (CMV) in transplant patients. A vaccine that increases CMV-specific T-cell responses could reduce CMV reactivation after …